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Dr Ross Bremner (Phoenix, Ariz). Thank you very much, and
congratulations on yet another great presentation and certainly
a very interesting and clearly written article.
The optimal drainage procedure for gastric interposition has
been debated perhaps even longer than the optimal treatment for
stage III lung cancer, but I will try to be brief. The idea of a quick
Botox injection is indeed intriguing, and although you do not mea-
sure the time it takes to do the Botox procedure versus a formal
pyloric procedure, I am sure your conclusion that it is quicker is
probably correct. I do have a couple of questions.
How exactly do you do this? How expensive is the drug, and do
you know intraoperatively that you have done it adequately? Can
you feel that the muscle is now paralyzed?
Dr Cerfolio. Thank you, and those are good questions. We do
not put a scope into the stomach and look endoscopically to ensure
proper placement, if that is what you mean. We do it by touch. The
pylorus is easily palpated. We inject Botox into it in all 4 quadrants,
and we are very careful on the side next to the gastroepiploic artery.
We inject the Botox in equal parts into all 4 quadrants. Because I
had really no baseline to go on, no previous publications on this
new idea to read, or anyone to ask, I just curb-sided my gastrointes-
tinal guys and decided to copy what they were doing endoscopi-
cally and do it open at the time of laparotomy. You can see the
Botox go into the pylorus; you get a little wheal when you are
injecting it sort of in the submucosal area, and then I just sort of
massage that in like a plastic surgeon does on the forehead. I
have talked to a couple plastic surgeons, and I guess that is what570 The Journal of Thoracic and Cardiovascular Surthey do when they do eyebrows and foreheads. Again, I just really
made this up.
Dr Bremner. How expensive is it?
Dr Cerfolio. It is expensive. Actually, it is interesting that the
billing office at the University of Alabama at Birmingham is very
aggressive with our operative notes, and they actually bill for it.
There is some code for chemodenervation of the muscle I see
when I get these operative notes to sign, and therefore one can
and should bill for it.
Dr Bremner. I am a little concerned about the temporary nature
of Botox. From the experience of gastroparesis and endoscopic Bo-
tox, we know that it lasts just about 3 to 5 months. In our cases in
which we have had to do a later operation to open up the pylorus for
gastric emptying, it is usually donemore than 6months later. I won-
der whether you have had any of your patients in whom you have
had to do an endoscopic redo Botox procedure if they had gastric
emptying problems?
Dr Cerfolio. We have not had to do that yet in the Botox group.
Now we certainly have used Botox in the other patients who have
very slow emptying, but I think that is much easier than a redo or
first-time pyloromyotomy after esophagectomy when the pylorus
is in no man’s land at the level of the diaphragm. I have never
gone back and had to reoperate on any of these patients for pyloric
obstruction, but we have used Botox in the other group, especially
in the group in which we did not do anything to the pylorus initially.
I think it works. But in those in whom we have treated the pylorus
initially with Botox, I have been thrilled with their emptying, even
after 3 to 5 months.
Dr Bremner. Do you have a very narrow conduit?
Dr Cerfolio. We tubularize the conduit to about 5 or 6 cm in
each patient. I think it is a real mistake to make the conduit too
wide or too redundant. I keep the stomach straight and narrow
and tall: a straight shot into the abdomen from the chest.
Dr Bremner. The study is unfortunately limited because you
stated here and well in the article that the objective data on long-
term emptying are not there, and I think it would be really nice if
you could do a radiographic emptying study, even on a subsection
of these patients. I mean, if you could just randomly select 20
patients from each of the groups and do an emptying study a year
or 2 down the line, it would be really nice to see what that it looks
like and perhaps even do a nuclear study to see whether there is any
bile reflux. Do you plan on doing something like that?
Dr Cerfolio. You are right, and we have some data on some of
the patients, but as I told Ayesha (and we all know Ayesha, she
was supposed to present this), unless you have the data for all
the patients, it does not make sense to show them for some pa-
tients. We really have data for only a few patients who were having
problems. I would argue that I am in this to take care of the patient.
If the patient is happy and swallowing well and maintaining his or
her weight, I do not care too much what it looks like on some
study, so why do it? I think our surveys, which were very accurate
and in which we used the same script on everybody, were our best
objective criteria of how they were swallowing. I think if we do
a prospective multi-institutional study on the best way to handle
the pylorus (ie, pyloromyotomy, nothing, or Botox), then we
will have to build the cost of that in. Also, it will be harder to
tell the patients that if they are doing well, they have to come
back and have a swallow test at 3 or 6 months, but that mightgery c March 2009
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Sbe the way to design it prospectively to really have data to answer
the question. I am biased now and would favor the Botox group
because I am convinced after doing all 3 procedures that it offers
the best results.
Dr Bremner. Finally, you noted that the chemoradiation group
had prolonged or delayed gastric emptying. Do you have a reason
for this?
Dr Cerfolio. Well, I do not know the exact reason. I can guess. I
am not sure, but I think it has to do with the fact that the conduit is
now being radiated. It clearly is in the radiated field and then on top
of a surgical manipulation, of grabbing it, stapling it, denervating it:
all those things together add up.
Dr Bremner. I think that possibly a narrow conduit or Botox
might be the answer, and I really look forward to participating in
a prospective trial like you mentioned. Thank you very much,
and thank you for the privilege of discussing the article.
Dr Cerfolio. Thank you.
Dr Richard Whyte (Stanford, Calif). Cerf, I enjoyed your arti-
cle. It was really very good. I have a quick question, though. You
had talked about using metoclopramide, erythromycin, and esome-
prazol in these patients. Did you use that same combination
throughout the years of the trial, or did that vary as well?
Dr Cerfolio. We were supposed to use it all the way through. If
you looked at some of the first patients, theymight not have gotten it
every day postoperatively, but everyone was supposed to receive it.
After that, though, our postoperative algorithmswerewell described
with high compliance, and thus the vastmajority of the patients have
been receiving them all. We do not use the metoclopramide out for
a month, but in the hospital we have been trying to do that. When I
was atMayo, I was lucky enough to spend timewithDrKeith Kelly,
who is a general surgeonwho spent a careerworking on gastric emp-
tying, and I spent 3monthswith him, so I alwayswas very interested
in gastric emptying, and we sort of stole some of his ideas for these
patients. It is not really in the thoracic literature, but Dr Jessica Don-
nington has written a nice chapter on the use of this treatment in the
thoracic surgical clinics.
Dr Donald Low (Seattle, Wash). First of all, as usual, this is
a very innovative, very interesting, and appropriate idea that we
should be looking at carefully regarding the management of these
patients. I notice that, first of all, you use the shotgun approach.
You start everything on everyone in every case before you do
your assessment.
Dr Cerfolio. Yes, just like I coach my Little League teams: we
come out running trying to steal bases early, and in basketball we
start off with a full-court press right out of the shoot. We come
out in the first inning and quarter and throw everything at them
to win the ballgame. Absolutely.
Dr Low. That is great. Maybe as far as winning that is good, but
maybe not for cost-effectiveness and assessing the results of overall
outcomes. First of all, you do not do a kocherization?
Dr Cerfolio. No.
Dr Low. For those of us who do this regularly, we recognize
sometimes the duodenum is very mobile. It is all ready. You can
move it right up to the esophageal hiatus. In other situations it is
very tacked down, and I think one of the issues regarding emptying
is making sure your conduit is verticalized and straight and that the
pylorus is sitting 2 to 3 cm below the hiatus in a straightforward
way. Do you not think that should be a part of the assessmentThe Journal of Thoracic and Cand the intraoperative aspects of what we are doing to ensure
good emptying at the time of surgical intervention?
Dr Cerfolio. It is a great question. It is one of the flaws of the
study course. One of the reasons I stopped doing a Kocher maneu-
ver is that I am not convinced that it makes a difference. But I totally
agree that the stomach should not be redundant or floppy because
over time it always gets worse. If you see those patients back at 3
or 4 years and if they are alive and they have a big floppy conduit,
they empty poorly. They look like they have long-standing achala-
sia with a sigmoid esophagus, and therefore I take out so much
stomach when I am in the chest, not as much in the neck, that I
asked myself why I was taking the time to do a Kocher maneuver
when I am resecting so much stomach. The conduit was still
straight and tall without the Kocher maneuver, it seemed. It took
time: not much, but some. There is some risk, but not much, but
everything is about efficiency and speed, and I think that the Kocher
maneuver did not make a difference. Now it is funny how some-
times you do not do a Kocher maneuver and yet sometimes you still
have a very nice straight column and sometimes you do not. If
someone has had a previous operation and they are socked in there,
I will take that down a little bit to try to ensure the conduit is ver-
tical, but I know that patients do not need a formal Kocher maneu-
ver to get a straight verticalized conduit.
Dr Low. One of the many things you are well known for is your
clinical pathways and fast tracking. I assume that includes the rein-
itiation of dietary profiles after surgical intervention.
Dr Cerfolio. Right.
Dr Low. What we have found is that some of the aspects of as-
piration, emptying, and so on have to do with what you are feeding
the patient, and a lot of the feedback we get has to do with that bar-
ium swallow that you do at 4 days. Do you think that we are too
far into clinical pathways and that we should be assessing these
swallows ourselves to assess how we should be introducing
erythromycin, metoclopramide, dietary profile, and Botox on an
individual basis rather than for baseball teams and for surgical
patients using.
Dr Cerfolio.. or basketball. That is another very good point. I
think that the team is the critical thing, and it is really not the sur-
geon. You guys know I am not modest, but it is the team, especially
with patients undergoing esophagectomy. I am, without a doubt,
the most easily replaced part of the team. We now have several
supernurses who just take care of the patients who have had esoph-
agectomies. We have a team of swallowing specialist nurses,
a speech and swallowing team that comes by and does these stud-
ies. We have radiologists who are very into doing this and making
sure—because we have had a death in the radiology suite after
a swallow—that it is being done correctly and safely. Therefore I
think your point is right. There are some patients in whom probably
you should not do a swallow test on the fourth or fifth day because it
is just not safe. They are not ready. They do not pass their bedside
swallow test, which we do on everyone first before we send them
for a swallow test. If they have poor emptying and a column of bar-
ium in their conduit, then the radiologist places a soft small catheter
through the anastomosis and sucks everything out to prevent aspi-
ration, but I think your point is well taken.
Dr Jemi Olak (Bakersfield, Calif). How did you measure bile
reflux in your patients in the postoperative period and then subse-
quently?ardiovascular Surgery c Volume 137, Number 3 571
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SDr Cerfolio. We did not measure it scientifically, as you sug-
gest, but we did measure it clinically. We have a survey that goes
all the way from what they eat and how they eat to looking at their
dumping symptoms. We ask things like whether they have any type
of sensation of things coming up. A lot of these people had endos-
copies afterward. Was there evidence of bile coming up? Pillow
staining was a specific question they were all asked to assess for572 The Journal of Thoracic and Cardiovascular Subile reflux as well. Therefore a very specific survey, I think, was
the best way I could get a handle on it, but you are right, it is not
scientific. It is not a radionucleotide tag particle that is bound to
the bile molecule to see whether it is coming up, which would be
nice but is really not practical or very cost-effective. Most impor-
tantly, if the patient is happy and asymptomatic, I am not sure
what I would do with that information.rgery c March 2009
